GSK announces start of phase I oncology study with ICOS agonist antibody

News Hour:

GSK today announced the start of a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costimulator (ICOS) agonist antibody. ICOS is a co-stimulatory receptor that enhances T-cell responses and results in an increased anti-tumour response from the immune system.

The study is a two-part clinical trial to evaluate the safety and pharmacokinetic / pharmacodynamic properties of GSK3359609 in patients with advanced/recurrent solid tumours. The study further aims to identify a dose suitable for development — as monotherapy in Part 1 and in combination with pembrolizumab (Keytruda®), MSD’s anti-PD-1 therapy, in Part 2. Anti-tumour activity will be evaluated as a secondary endpoint in the study.

  Learn about the COVID-19 pandemic from News Hour  

onkologija

Axel Hoos, Senior Vice President and Therapeutic Area Head of Oncology said: “We are at a very exciting point in the development of new immuno-oncology agents which have the potential to expand the results seen with checkpoint inhibitors. Novel targets like ICOS will be at the forefront of these new agents and this study will give us the first look at the effects of stimulating the immune system by activating the ICOS receptor.”

GSK3359609 is an investigational product and is not approved for use anywhere in the world. It is the third of four immuno-oncology assets profiled to investors at GSK’s R&D event in November 2015 to enter the clinic. The company’s Oncology portfolio is one of six core areas of scientific research and development, alongside immuno-inflammation, vaccines and infectious, respiratory and rare diseases.

Follow News Hour
Mehrab Masayeed Habib

Mehrab Masayeed Habib studied Electrical and Electronics Engineering (EEE) at American International University Bangladesh (AIUB). Currently, he is working for News Hour. He is passionate about automobiles. He is also the founder & trainer of Bangla Automobile School. He conducts workshops on automobile engineering at local level.
No Comments
Scroll Up
%d bloggers like this: